trending Market Intelligence /marketintelligence/en/news-insights/trending/NUaofcZhxx0LtxE0KC3JHg2 content esgSubNav
In This List

Samsung Bioepis ties with 3SBio to expand into China


Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


S&P Capital IQ Pro | Powered by Advanced Visualization


S&P Capital IQ Pro | Unrivaled Sector Coverage


S&P Capital IQ Pro | Powering Your Edge

Samsung Bioepis ties with 3SBio to expand into China

Samsung Bioepis Co. Ltd. said the company will partner with Hong Kong-listed 3SBio Inc. to develop and commercialize multiple of its biosimilar drugs in China.

Samsung Bioepis has not yet released any drug in China. The two companies will work together in clinical trials, regulatory registration, commercialization and other areas in China for Samsung Bioepis' drugs including cancer therapy SB8, a biosimilar of bevacizumab, also known as Avastin.

SB8 will focus on metastatic colon cancer and non-small cell lung cancer indications in China.

According to the Jan. 6 news release, Samsung Bioepis will manufacture and supply the drugs. It will receive an up-front payment, royalties on sales and milestone payments from the cooperation.

Further financial terms of the collaboration agreement were not disclosed.

Samsung Bioepis is a joint venture established by Samsung Biologics Co. Ltd. and U.S.-based Biogen Inc. in 2012. 3SBio has more than 30 products under development, targeting oncology, auto-immune diseases and other illnesses.

Separately, South Korean biotech company Celltrion Inc. said it will build a joint venture in China in 2019.